Have you seen us on TV? Watch Now

Medical Educational Resource

We're accelerating the delivery of treatments and cures.

The role of complement in ALS and the MERIDIAN study of pegcetacoplan in sporadic ALS

Activity Snapshot

Activity Type: 
On-Demand Webinar
Release Date: 
Monday, July 19, 2021
Sponsor Information: 

This Industry Update Webinar is sponsored by Apellis. This program is not sponsored, endorsed, or accredited by MDA.


Dr. Rup Tandan
Attending Neurologist, University of Vermont Medical Center
Activity Overview: 

This webinar discusses the role of complement mediated neuroinflammation and complement component C3 in ALS disease and progression followed by an overview of the ongoing Phase 2, placebo controlled, study of the C3 inhibitor pegcetacoplan in ALS.  The featured presenter of this Industry Update Webinar is Dr. Rup Tandan from the University of Vermont Medical Center. This Industry Update Webinar is sponsored by Apellis.